12-6　ⓔ文献

  1. 尾崎米厚，松下幸生，他：わが国の成人飲酒行動及びアルコール症に関する全国調査．アルコール研究と薬物依存，2005; 40: 455–470.

  2. 鈴木康秋，大竹孝明，他：我が国における非B非C肝硬変の実態．我が国における非B非C肝硬変の実態調査2011 (青栁　豊，橋本悦子，他編)，響文社，2012; 6–16.

  3. 泉並木，玉城信治：肝硬変の成因別実態2014全国の集計．肝硬変の成因別実態，医学図書出版，2015.

  4. 尾崎米厚：わが国における飲酒行動の実態及びアルコール性肝障害の疫学．NASH・アルコール性肝障害の診療を極める (竹井謙之編)，Hepatology Practice Vol. 2，文光堂，2013; 226–230.

  5. Teli MR, Day CP, et al: Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet, 1995; 346: 987–990.

  6. Galambos JT: Natural history of alcoholic hepatitis. 3. Histological changes. Gastroenterology, 1972; 63: 1026–1035.

  7. Forrest EH, Evans CD, et al: Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut, 2005; 54: 1174–1179.

  8. Enomoto N, Takase S, et al: Alcoholic liver disease in heterozygotes of mutant and normal dehydrogenase–2 genes. Hepatology, 1991; 13: 1071–1075.

  9. 竹井謙之：アルコール性肝障害の病態概念の変遷．NASH・アルコール性肝障害の診療を極める (竹井謙之編)，Hepatology Practice Vol. 2, 文光堂，2013; 214–220.

  10. Sugimoto K, Takei Y: Pathogenesis of alcoholic liver disease. Hepatol Res, 2017; 47: 70–79.

  11. Enomoto N, Ikejima K, et al: Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin. Gastroenterology, 1998; 115: 443–451.

  12. Becker U, Deis A, et al: Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology, 1996; 23: 1025–1029.

  13. アルコール医学生物学研究会編：アルコール性肝障害診断基準2011年版，響文社，2012.

  14. Pessione F, Ramond MJ, et al: Five–year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int, 2003; 23: 45–53.

  15. Stickel F, Hoehn B, et al: Review article: Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther, 2003; 18: 357–373.

  16. Louvet A, Thursz MR, et al: Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo: a meta–analysis of individual data from controlled trials. Gastroenterology, 2018; 155: 458–468.